Skip to main content

20-05-2019 | Chronic obstructive pulmonary disease | Video

ATS 2019: No reduction in COPD exacerbation rate with benralizumab treatment

Gerard Criner reports findings from the placebo-controlled GALATHEA and TERRANOVA trials, demonstrating that add-on benralizumab does not reduce exacerbation rates among patients with moderate to very severe chronic obstructive pulmonary disease (3:27).

Funding for independent interviews at ATS 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.